NewsBenzingaグッゲンハイム、トラヴェレ・セラピューティクスの「買い」判断を維持、目標株価を78ドルに引き下げ グッゲンハイム、トラヴェレ・セラピューティクスの「買い」判断を維持、目標株価を78ドルに引き下げ Benzinga 2026.11.04 15:19 (GMT+0) Open on Benzinga Other news 'Meta Acquires AI Coding Startup Conductor' - Axios Exclusive Morgan Stanley Maintains Equal-Weight on Upstart Holdings, Lowers Price Target to $24 Morgan Stanley Maintains Equal-Weight on Ultragenyx Pharmaceutical, Raises Price Target to $22 CAVA Earnings Preview: Kalshi Traders Bet on Cyclospora Talk as Sales Recovery Faces Test Waymo confirms it will split with Uber in January 2028 Morgan Stanley Maintains Overweight on Keurig Dr Pepper, Raises Price Target to $40
